Anticoagulation-free VV ECMO for Acute Respiratory Failure
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorDamian Ratano
About this trial
Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an "anticoagulation-free strategy" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).
Eligibility criteria
Qualifiers
Adult patient with ARDS on VV-ECMO
Disqualifiers
Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia, active hemorrhage, any surgery precluding the use of anticoagulation),
Indication for therapeutic anticoagulation (pulmonary embolism or deep vein thrombosis, chronic anticoagulation therapy before ECMO insertion)
Low-flow (<2 liters/min) VV-ECMO (ECCO2R)
Trial design
Treatments tested in this trial
- Subcutaneous Heparin
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Damian Ratano
Lead sponsor
University Health Network, Toronto
Sponsor institution
The Physicians' Services Incorporated Foundation
Collaborator
Source ClinicalTrials.gov